Diane Peters is an Assistant Professor of Pharmacology and Molecular Sciences at the Johns Hopkins School of Medicine. She received her BA in Chemistry, with honors, from Wellesley College, followed by pursuit of a PhD in Pharmacology and Experimental Therapeutics from the Tufts University School of Medicine. Subsequently, she earned an MS in laboratory animal medicine as well as a doctorate of veterinary medicine, both granted by the Tufts University School of Veterinary Medicine. Dr. Peters performed her post-graduate fellowship training in laboratory animal medicine at the Johns Hopkins University School of Medicine, where she further refined research expertise in comparative medicine, translational drug discovery, and animal pharmacology/toxicology. Barbara Slusher is a Professor of Neurology (primary), Pharmacology and Molecular Sciences, Psychiatry, Neuroscience, Medicine, and Oncology at Johns Hopkins School of Medicine. She also serves as the Director of the Johns Hopkins Drug Discovery, the Vice Director of the Pedersen Brain Science Institute, and the Co-Director of the Johns Hopkins Center for the Advancement of HIV Neurotherapeutics (JH CAHN). She has published over 300 scientific articles and is an inventor on over100 patents and applications. Before joining Johns Hopkins, she spent 18 years in the pharmaceutical industry, including several years at the level of Senior Vice President of Research and Translational Development. She has extensive experience in drug discovery through early clinical development and was involved in the successful development, launch and/or post marketing support of several FDA-approved medicines. In 2010, she joined Johns Hopkins to lead the largest drug discovery program on campus with a veteran team of over 25 medicinal chemists, assay developers, pharmacologists, toxicologists, and pharmacokinetics/drug metabolism experts. The team identifies novel drug targets and translates them into new drug therapies for clinical development. Since joining JHU, she has co-founded four new companies which have amassed over $150M in financing and has partnered four new drug discovery programs with Pharma. She also founded the first International Consortium of Academic Drug Discovery Centers (http://addconsortium.org/) with over 150 university-led translational centers and 1500 members to bring together this growing community. Dr. Slusher received her undergraduate degree from Dickinson College where she graduated valedictorian, majoring in Chemistry. She received her Ph.D. in Pharmacology and Molecular Sciences from the Johns Hopkins School of Medicine while simultaneously earning her Master's degree in Administrative Science from the Johns Hopkins Carey School of Business (formerly School of Continuing Studies). Subashchandrabose Chinnathambi is Additional Professor at the Department of Neurochemistry, National Institute of Mental Health and Neurosciences Hospital Bangalore, Karnataka, India. His scientific interests include physiopathology of neurodegenerative disorders, Tau Cytoskeleton, Tau-GPCR, purinergic and chemokine receptors, Tau stem cells, animal models, neuropharmacology, therapeutic approaches targeting Tau oligomers, and biomarkers for neurodegeneration. He serves on the editorial board for various international cell biology journals and is also a regular invited speaker at a number of meetings and workshops. Dr. Chinnathambi has more than 16 years of research experience in the area of neuroscience and Tau-related research in Alzheimer’s Disease.

• 1. Tauopathies and its therapeutic interventions in Alzheimer’s diseaseSubashchandrabose Chinnathambi2. Biomarkers of Alzheimer's and Parkinson’s diseaseSaroj Kumar3. Pharmacological targets for Parkinson's diseaseAbhishek Kumar Mishra and Dipak Kumar4. Natural products in Parkinsons diseaseS.P. Singh5. Neurodegeneration of α-synuclein in Parkinson's diseaseMeghana Tare6. Targeting NLRP3 inflammasome for AD/PDGaurav Gupta7. Pax6 in Alzheimer's and Parkinson's DiseaseRajnikant Mishra8. Phamacological applications for AD/PDAshok Kumar Datusalia9. Multitarget Approaches in the Treatment of Alzheimer's Disease: A New Strategy in Drug DesignJemmyson Romário de Jesus10. Phamacological applications for AD/PDAshok Kumar Datusalia11. Podosomes in Alzheimer’s and Parkinson’s diseaseSubashchandrabose Chinnathambi12. Histone Deacetylases in Neurodegenerative/ Alzheimers diseasesAbhishek Balmik13. Translational Pharmacological Interventions Targeting Amyloidogenic Mechanisms in Parkinson's Disease and Alzheimer's DiseaseMahesh Kandasamy, Gowsika Baskar, Jayaprakash Senthil, Preeti Singh, Abirami Thiyagasundar14. LRRK2 and Nrf2 Regulation in Parkinson’s Disease: Mechanistic Insights and Therapeutic PotentialVijay Kumar Prajapati15. Neural Receptors as the Gateway to Neuroprotection: The Current Landscape of Parkinson’s TherapeuticsMurugan Sevanan16. Actin Cytoskeletal Pathology in Alzheimer’s DiseaseSubashchandrabose Chinnathambi17. Tau propagation models in ADGhulam Jeelani Pir18. Nanoparticles targets for Alzheimer's and Parkinson's diseaseSharda Bharti19. Signaling cascades of Chemokine receptors in Parkinson’s diseaseMadhura Chandrashekar20. Synaptic plasticity in Alzheimer’s diseasePoornima Priyadarshini21. Cytokine synthesis and membrane-associated actin remodelling in AD microgliaHariharakrishnan Chidambaram22. Recent Advances in Biopolymeric Nanocarriers Based on Metallodrugs for Therapeutic Intervention in Neurodegenerative DiseasesJemmyson Romário de Jesus23. Modulating the Interactions between Amyloid-Beta, Tau, and Metals: Emerging Pharmacological Approaches in Alzheimer's DiseaseJemmyson Romário de Jesus24. Pyk2 dysregulation in Alzheimer's diseaseAparna Banerjee Dixit25. Are Lewy body dementia and Parkinson's disease dementia being the same thing, or are they different: the role of neurochemical bio markersSubashchandrabose Chinnathambi26. Blood-based biomarker analysis of Alzheimer’s disease by proteomics profilingSubashchandrabose Chinnathambi

Diane Peters is an Assistant Professor of Pharmacology and Molecular Sciences at the Johns Hopkins School of Medicine. She received her BA in Chemistry, with honors, from Wellesley College, followed by pursuit of a PhD in Pharmacology and Experimental Therapeutics from the Tufts University School of Medicine. Subsequently, she earned an MS in laboratory animal medicine as well as a doctorate of veterinary medicine, both granted by the Tufts University School of Veterinary Medicine. Dr. Peters performed her post-graduate fellowship training in laboratory animal medicine at the Johns Hopkins University School of Medicine, where she further refined research expertise in comparative medicine, translational drug discovery, and animal pharmacology/toxicology. Barbara Slusher is a Professor of Neurology (primary), Pharmacology and Molecular Sciences, Psychiatry, Neuroscience, Medicine, and Oncology at Johns Hopkins School of Medicine. She also serves as the Director of the Johns Hopkins Drug Discovery, the Vice Director of the Pedersen Brain Science Institute, and the Co-Director of the Johns Hopkins Center for the Advancement of HIV Neurotherapeutics (JH CAHN). She has published over 300 scientific articles and is an inventor on over100 patents and applications. Before joining Johns Hopkins, she spent 18 years in the pharmaceutical industry, including several years at the level of Senior Vice President of Research and Translational Development. She has extensive experience in drug discovery through early clinical development and was involved in the successful development, launch and/or post marketing support of several FDA-approved medicines. In 2010, she joined Johns Hopkins to lead the largest drug discovery program on campus with a veteran team of over 25 medicinal chemists, assay developers, pharmacologists, toxicologists, and pharmacokinetics/drug metabolism experts. The team identifies novel drug targets and translates them into new drug therapies for clinical development. Since joining JHU, she has co-founded four new companies which have amassed over $150M in financing and has partnered four new drug discovery programs with Pharma. She also founded the first International Consortium of Academic Drug Discovery Centers (http://addconsortium.org/) with over 150 university-led translational centers and 1500 members to bring together this growing community. Dr. Slusher received her undergraduate degree from Dickinson College where she graduated valedictorian, majoring in Chemistry. She received her Ph.D. in Pharmacology and Molecular Sciences from the Johns Hopkins School of Medicine while simultaneously earning her Master's degree in Administrative Science from the Johns Hopkins Carey School of Business (formerly School of Continuing Studies). Subashchandrabose Chinnathambi is Additional Professor at the Department of Neurochemistry, National Institute of Mental Health and Neurosciences Hospital Bangalore, Karnataka, India. His scientific interests include physiopathology of neurodegenerative disorders, Tau Cytoskeleton, Tau-GPCR, purinergic and chemokine receptors, Tau stem cells, animal models, neuropharmacology, therapeutic approaches targeting Tau oligomers, and biomarkers for neurodegeneration. He serves on the editorial board for various international cell biology journals and is also a regular invited speaker at a number of meetings and workshops. Dr. Chinnathambi has more than 16 years of research experience in the area of neuroscience and Tau-related research in Alzheimer’s Disease.

• 1. Tauopathies and its therapeutic interventions in Alzheimer’s diseaseSubashchandrabose Chinnathambi2. Biomarkers of Alzheimer's and Parkinson’s diseaseSaroj Kumar3. Pharmacological targets for Parkinson's diseaseAbhishek Kumar Mishra and Dipak Kumar4. Natural products in Parkinsons diseaseS.P. Singh5. Neurodegeneration of α-synuclein in Parkinson's diseaseMeghana Tare6. Targeting NLRP3 inflammasome for AD/PDGaurav Gupta7. Pax6 in Alzheimer's and Parkinson's DiseaseRajnikant Mishra8. Phamacological applications for AD/PDAshok Kumar Datusalia9. Multitarget Approaches in the Treatment of Alzheimer's Disease: A New Strategy in Drug DesignJemmyson Romário de Jesus10. Phamacological applications for AD/PDAshok Kumar Datusalia11. Podosomes in Alzheimer’s and Parkinson’s diseaseSubashchandrabose Chinnathambi12. Histone Deacetylases in Neurodegenerative/ Alzheimers diseasesAbhishek Balmik13. Translational Pharmacological Interventions Targeting Amyloidogenic Mechanisms in Parkinson's Disease and Alzheimer's DiseaseMahesh Kandasamy, Gowsika Baskar, Jayaprakash Senthil, Preeti Singh, Abirami Thiyagasundar14. LRRK2 and Nrf2 Regulation in Parkinson’s Disease: Mechanistic Insights and Therapeutic PotentialVijay Kumar Prajapati15. Neural Receptors as the Gateway to Neuroprotection: The Current Landscape of Parkinson’s TherapeuticsMurugan Sevanan16. Actin Cytoskeletal Pathology in Alzheimer’s DiseaseSubashchandrabose Chinnathambi17. Tau propagation models in ADGhulam Jeelani Pir18. Nanoparticles targets for Alzheimer's and Parkinson's diseaseSharda Bharti19. Signaling cascades of Chemokine receptors in Parkinson’s diseaseMadhura Chandrashekar20. Synaptic plasticity in Alzheimer’s diseasePoornima Priyadarshini21. Cytokine synthesis and membrane-associated actin remodelling in AD microgliaHariharakrishnan Chidambaram22. Recent Advances in Biopolymeric Nanocarriers Based on Metallodrugs for Therapeutic Intervention in Neurodegenerative DiseasesJemmyson Romário de Jesus23. Modulating the Interactions between Amyloid-Beta, Tau, and Metals: Emerging Pharmacological Approaches in Alzheimer's DiseaseJemmyson Romário de Jesus24. Pyk2 dysregulation in Alzheimer's diseaseAparna Banerjee Dixit25. Are Lewy body dementia and Parkinson's disease dementia being the same thing, or are they different: the role of neurochemical bio markersSubashchandrabose Chinnathambi26. Blood-based biomarker analysis of Alzheimer’s disease by proteomics profilingSubashchandrabose Chinnathambi

Diane Peters is an Assistant Professor of Pharmacology and Molecular Sciences at the Johns Hopkins School of Medicine. She received her BA in Chemistry, with honors, from Wellesley College, followed by pursuit of a PhD in Pharmacology and Experimental Therapeutics from the Tufts University School of Medicine. Subsequently, she earned an MS in laboratory animal medicine as well as a doctorate of veterinary medicine, both granted by the Tufts University School of Veterinary Medicine. Dr. Peters performed her post-graduate fellowship training in laboratory animal medicine at the Johns Hopkins University School of Medicine, where she further refined research expertise in comparative medicine, translational drug discovery, and animal pharmacology/toxicology. Barbara Slusher is a Professor of Neurology (primary), Pharmacology and Molecular Sciences, Psychiatry, Neuroscience, Medicine, and Oncology at Johns Hopkins School of Medicine. She also serves as the Director of the Johns Hopkins Drug Discovery, the Vice Director of the Pedersen Brain Science Institute, and the Co-Director of the Johns Hopkins Center for the Advancement of HIV Neurotherapeutics (JH CAHN). She has published over 300 scientific articles and is an inventor on over100 patents and applications. Before joining Johns Hopkins, she spent 18 years in the pharmaceutical industry, including several years at the level of Senior Vice President of Research and Translational Development. She has extensive experience in drug discovery through early clinical development and was involved in the successful development, launch and/or post marketing support of several FDA-approved medicines. In 2010, she joined Johns Hopkins to lead the largest drug discovery program on campus with a veteran team of over 25 medicinal chemists, assay developers, pharmacologists, toxicologists, and pharmacokinetics/drug metabolism experts. The team identifies novel drug targets and translates them into new drug therapies for clinical development. Since joining JHU, she has co-founded four new companies which have amassed over $150M in financing and has partnered four new drug discovery programs with Pharma. She also founded the first International Consortium of Academic Drug Discovery Centers (http://addconsortium.org/) with over 150 university-led translational centers and 1500 members to bring together this growing community. Dr. Slusher received her undergraduate degree from Dickinson College where she graduated valedictorian, majoring in Chemistry. She received her Ph.D. in Pharmacology and Molecular Sciences from the Johns Hopkins School of Medicine while simultaneously earning her Master's degree in Administrative Science from the Johns Hopkins Carey School of Business (formerly School of Continuing Studies). Subashchandrabose Chinnathambi is Additional Professor at the Department of Neurochemistry, National Institute of Mental Health and Neurosciences Hospital Bangalore, Karnataka, India. His scientific interests include physiopathology of neurodegenerative disorders, Tau Cytoskeleton, Tau-GPCR, purinergic and chemokine receptors, Tau stem cells, animal models, neuropharmacology, therapeutic approaches targeting Tau oligomers, and biomarkers for neurodegeneration. He serves on the editorial board for various international cell biology journals and is also a regular invited speaker at a number of meetings and workshops. Dr. Chinnathambi has more than 16 years of research experience in the area of neuroscience and Tau-related research in Alzheimer’s Disease.

• 1. Tauopathies and its therapeutic interventions in Alzheimer’s diseaseSubashchandrabose Chinnathambi2. Biomarkers of Alzheimer's and Parkinson’s diseaseSaroj Kumar3. Pharmacological targets for Parkinson's diseaseAbhishek Kumar Mishra and Dipak Kumar4. Natural products in Parkinsons diseaseS.P. Singh5. Neurodegeneration of α-synuclein in Parkinson's diseaseMeghana Tare6. Targeting NLRP3 inflammasome for AD/PDGaurav Gupta7. Pax6 in Alzheimer's and Parkinson's DiseaseRajnikant Mishra8. Phamacological applications for AD/PDAshok Kumar Datusalia9. Multitarget Approaches in the Treatment of Alzheimer's Disease: A New Strategy in Drug DesignJemmyson Romário de Jesus10. Phamacological applications for AD/PDAshok Kumar Datusalia11. Podosomes in Alzheimer’s and Parkinson’s diseaseSubashchandrabose Chinnathambi12. Histone Deacetylases in Neurodegenerative/ Alzheimers diseasesAbhishek Balmik13. Translational Pharmacological Interventions Targeting Amyloidogenic Mechanisms in Parkinson's Disease and Alzheimer's DiseaseMahesh Kandasamy, Gowsika Baskar, Jayaprakash Senthil, Preeti Singh, Abirami Thiyagasundar14. LRRK2 and Nrf2 Regulation in Parkinson’s Disease: Mechanistic Insights and Therapeutic PotentialVijay Kumar Prajapati15. Neural Receptors as the Gateway to Neuroprotection: The Current Landscape of Parkinson’s TherapeuticsMurugan Sevanan16. Actin Cytoskeletal Pathology in Alzheimer’s DiseaseSubashchandrabose Chinnathambi17. Tau propagation models in ADGhulam Jeelani Pir18. Nanoparticles targets for Alzheimer's and Parkinson's diseaseSharda Bharti19. Signaling cascades of Chemokine receptors in Parkinson’s diseaseMadhura Chandrashekar20. Synaptic plasticity in Alzheimer’s diseasePoornima Priyadarshini21. Cytokine synthesis and membrane-associated actin remodelling in AD microgliaHariharakrishnan Chidambaram22. Recent Advances in Biopolymeric Nanocarriers Based on Metallodrugs for Therapeutic Intervention in Neurodegenerative DiseasesJemmyson Romário de Jesus23. Modulating the Interactions between Amyloid-Beta, Tau, and Metals: Emerging Pharmacological Approaches in Alzheimer's DiseaseJemmyson Romário de Jesus24. Pyk2 dysregulation in Alzheimer's diseaseAparna Banerjee Dixit25. Are Lewy body dementia and Parkinson's disease dementia being the same thing, or are they different: the role of neurochemical bio markersSubashchandrabose Chinnathambi26. Blood-based biomarker analysis of Alzheimer’s disease by proteomics profilingSubashchandrabose Chinnathambi